Vall d'Hebron Hospital Universitari Reports Findings in Inflammatory Bowel Disease (The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic...).

A recent study conducted at Vall d'Hebron Hospital Universitari in Barcelona, Spain, aimed to develop a population pharmacokinetic (PopPK) model of infliximab in pediatric patients with inflammatory bowel disease (IBD). The study analyzed the effect of single nucleotide polymorphisms (SNPs) and other biomarkers on infliximab clearance. The researchers found that a PopPK model utilizing weight, albumin, faecal calprotectin, erythrocyte sedimentation rate, and the SNP rs1048610 accurately predicted infliximab trough concentrations in children with IBD. This research provides valuable insights into personalized dosing strategies for infliximab in pediatric IBD patients. [Extracted from the article]

Copyright of Pediatrics Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)